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Altered gut microbiota in infants is
associated with respiratory syncytial virus
disease severity
Jeffrey N. Harding1,2, David Siefker1,2, Luan Vu1,2, Dahui You3,4, John DeVincenzo3,4, JF. Pierre3,4 and
Stephania A. Cormier1,2*
Abstract
Background: Respiratory syncytial virus (RSV) is the number one cause of lower respiratory tract infections in
infants. There are still no vaccines or specific antiviral therapies against RSV, mainly due to the inadequate
understanding of RSV pathogenesis. Recent data suggest a role for gut microbiota community structure in
determining RSV disease severity. Our objective was to determine the gut microbial profile associated with severe
RSV patients, which could be used to help identify at-risk patients and develop therapeutically protective microbial
assemblages that may stimulate immuno-protection.
Results: We enrolled 95 infants from Le Bonheur during the 2014 to 2016 RSV season. Of these, 37 were well-
babies and 58 were hospitalized with RSV. Of the RSV infected babies, 53 remained in the pediatric ward
(moderate) and 5 were moved to the pediatric intensive care unit at a later date (severe). Stool samples were
collected within 72 h of admission; and the composition of gut microbiota was evaluated via 16S sequencing of
fecal DNA. There was a significant enrichment in S24_7, Clostridiales, Odoribacteraceae, Lactobacillaceae, and
Actinomyces in RSV (moderate and severe) vs. controls. Patients with severe RSV disease had slightly lower alpha
diversity (richness and evenness of the bacterial community) of the gut microbiota compared to patients with
moderate RSV and healthy controls. Beta diversity (overall microbial composition) was significantly different
between all RSV patients (moderate and severe) compared to controls and had significant microbial composition
separating all three groups (control, moderate RSV, and severe RSV).
Conclusions: Collectively, these data demonstrate that a unique gut microbial profile is associated with RSV disease and
with severe RSV disease with admission to the pediatric intensive care unit. More mechanistic experiments are needed to
determine whether the differences observed in gut microbiota are the cause or consequences of severe RSV disease.
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Background
Respiratory syncytial virus (RSV) is a ubiquitous respiratory
virus infecting the majority of the human population by 1
year of age [1]. While most infants develop mild upper
respiratory tract infections (URTI), 0.5–2% develop severe,
lower respiratory tract infections (LRTI), including bron-
chiolitis and pneumonia, requiring hospitalization [2]. Each
year, RSV causes 33 million cases and 3.4 million hospitali-
zations worldwide in children under 5 years of age [3]. In
the U.S. alone, RSV causes 85,000 to 144,000 hospitaliza-
tions [4], 14,000 deaths [2], and ~ $2.6 billion in medical care
costs each year [5]. Despite the substantial RSV-associated
medical and economic burden worldwide, a vaccine for RSV
currently remains elusive. The only prevention for infants at
high-risk for complications (i.e., premature or underlying
immune/cardiopulmonary diseases) is in the form of a
monoclonal antibody, palivizumab. In view of the fact that
RSV is a “significant unmet medical need” [6] with no
known vaccine, there is a necessity to find therapeutic
approaches to prevent and treat severe RSV infections.
The recently discovered relationship between respira-
tory health and gut microbiome dysbiosis has attracted
growing interest for therapeutic manipulation to im-
prove vaccine effectiveness and to allow for alternative
therapies for viruses with no known vaccines, like RSV.
Clinical studies demonstrate that prebiotic and probiotic
supplementation alters gut microbiota [7], reduces the
incidence of rhinovirus infections in preterm infants [8],
and reduces rhinovirus infection duration and severity in
adults [9]. In mice, gut microbial dysbiosis induced by
antibiotic treatment inhibits pulmonary type I interferons
(IFNs) and T cell responses, resulting in increased lung
viral loads after infection with influenza virus [10, 11]. On
the other hand, supplementing mice with Lactobacillus
plantarum promotes type I IFNs and reduces influenza
viral load in the lung [12]. In mice, both RSV and influ-
enza virus infection alters the gut microbiome and pro-
vides preferential growth environments for the S24_7
family showing a correlation between S24_7 family and
RSV infection, although the mechanism is still unknown
[13]. Several reports have studied the association of airway
microbiota with RSV severity [14, 15]; nevertheless, there
have been no studies that directly investigated the role of
gut microbiota in the severity of RSV infections.
We hypothesize that gut microbiota could play an
essential role in the pathogenesis of RSV in infants. This
study characterizes the gut microbiome in infants hospi-
talized with RSV infection differentiating severe infec-
tions requiring infants to be put into pediatric intensive
care unit (PICU) and moderate infections of infants in
the general ward. Our results demonstrate that there is a
relationship between RSV infection and gut microbiome
that could conceivably be interrogated to develop a use-
ful therapeutic target to prevent severe RSV disease.
Results
Characteristics of study population
Our study population included 37 patients enrolled from
Le Bonheur Outpatient Clinic during well-baby checkup
(control) and 58 patients admitted to the general ward
(moderate), who tested positive for RSV and negative for
influenza by RT-PCR. Samples were collected from pa-
tients during the 2014 to 2016 RSV seasons. Subsequent
to enrollment, 5 patients were moved from the general
ward to the pediatric intensive care unit (PICU). These
patients were classified as severe. None of the enrolled
patients received antibiotics prior to sample collection.
Control, moderate, and severe patients had an average
age of 93, 94, and 60 days, respectively (p = 0.284;
Table 1). The majority of moderate and severe patients
had O2 supplementation (p = < 0.001) and wheezing
(p = 0.011) compared to the control group. From patient
enrollment forms, there were no significant differences
in the average time of symptom onset in moderate pa-
tients (6.82 days) compared to severe patients (7.33 days).
As both wheezing and O2 supplementation is commonly
associated with RSV, this correlation is not surprising.
However, the only significant difference observed be-
tween the RSV groups (moderate and severe) regarding
all demographic metadata was in the family history of
asthma due to none of the severe patients having a fam-
ily history of asthma (Table 1).
The gut microbiome
Although the role of gut microbiota in regulating the
immune system and respiratory infections is being in-
creasingly recognized, the role of gut microbiota in RSV
disease severity has never been addressed in infant
humans. Here, we analyzed the gut microbiota from in-
fants hospitalized with RSV. The patient fecal DNA was
isolated for microbiome analysis by 16S rRNA sequen-
cing (Fig. 1a). Resulting sequencing data was analyzed
using Qiime 2 pipeline with a 99% OTU identification
by GreenGenes database (Fig. 1b).
Gut microbiome richness is reduced in severe RSV
infected patients
To examine the gut microbiota in RSV patients, we de-
termined the α-diversity in the stool samples using
Chao1 index and Shannon index in QIIME 2 with sam-
ples rarefied to a read depth of 6682 to ensure that a
reasonable number of sequence reads have been ob-
tained for each OTU (Supplemental Figure 1A). There
was no difference in the species richness and evenness
(α-diversity) of gut microbiome between RSV patients
and control patients (Fig. 2a, b). We further segregated
the RSV patients into moderate and severe RSV patients
(based on their PICU status) to determine if there are
differences in gut microbiome as a result of severity of
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Table 1. Participant characteristics of healthy controls and infants hospitalized with RSV
P values in the table were calculated using Fisher’s Exact test
Fig. 1 Sample collection process and data analysis workflow. a Workflow from sample collection to sequence data. b Data analysis workflow in
Qiime 2 and Galaxy
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RSV disease. Although it failed to reach significance, pa-
tients with severe RSV (PICU) had a slightly reduced
species richness and evenness in the gut microbiota
compared to that of control and moderate RSV (non-
PICU) patients using both Shannon index and Chao1
index (Fig. 2c, d).
Gut microbiome phylogenetic diversity shows significant
clustered populations in RSV disease severity
In addition to richness and evenness of gut microbiota,
we determined the overall qualitative relatedness of
phylogenetic distances (β-diversity). Significant differ-
ences were found in microbiome composition between
RSV and control group as well as between RSV disease
severities. We applied the multivariate method of PER-
MANOVA with 999 permutations using unweighted and
weighted UniFrac distance matrix (P < 0.0001 and P =
0.031, respectively). In addition, we used multivariate re-
dundant discriminant analysis (RDA) at the OTU level
to visualize the separation of RSV and the control
groups (Fig. 3a). The patients were further distinguished
into groups by disease severity (Fig. 3b). This showed
Fig. 2 α-diversity is not significantly reduced in severe RSV infected patients compared to healthy controls. a Shannon Index of the gut
microbiota shows no difference between healthy controls (n = 37) and infants with RSV disease (n = 58). b Chao1 Index of the gut microbiota
shows no difference between healthy controls (n = 37) and infants with RSV disease (n = 58). c Shannon Index is slightly reduced in severe RSV
disease (n = 5) compared to healthy controls (n = 37) or infants with moderate RSV disease (n = 53) but is not significant. d Chao1 Index shows no
difference in severe RSV disease (n = 5) compared to healthy controls (n = 37) and infants with moderate RSV disease (n = 53). Each point
represents an individual infant and the mean ± SEM
Fig. 3 RDA plots show separate phylogenetic clustering for control and RSV patients. Gut microbiome composition in infants infected with RSV
and healthy control infants were analyzed using RDA to visualize the phylogenetic dissociations in RSV infected patients compared to healthy
controls. a Control patients cluster separately from moderate or severe RSV patients on a phylogenetic basis. b Severe RSV patients cluster
separately from control and moderate RSV patients showing a significantly different phylogenetic composition
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that there were not only statistically significant differ-
ences between the control and RSV patients, but there
was a further separation between severity of RSV in the
patients (P < 0.05). To expand our understanding of the
phylogenetic differences driving the separation of
clusters, we performed Linear Discriminate Analysis of
Effect size (LEfSe) analysis to identify enriched taxa that
best characterize the alterations in the severe, moderate,
and control patients by coupling standard tests for statis-
tical significance and biological relevance through prior
knowledge stored in databases such as KEGG, SEED,
COGs, etc.. We were able to identify the key phylotypes
that could be used as biomarkers at different phylogen-
etic levels to discriminate between control, moderate,
and severe RSV (Fig. 4; Supplemental Figures 2 and 3).
LEfSe comparison of the gut microbiota highlights the
distinctive microbial profile of patients with severe dis-
ease. The taxa in gray show the specific microbial groups
that are enriched in the severe patients when comparing
to the moderate and control groups. The blue and the
red colors show the specific microbial groups that are
enriched in the microbiome for moderate and control
patients, respectively. Due to the fact that LEfSe includes
biologically informative clades differentiating two or
more phenotypes, this may be important for clinical
therapeutics. On a family level we see that S24_7 and
Odoribacteraceae are associated with severe RSV, while
Clostridiales and Lactobacillaceae are characteristic of
moderate RSV (Fig. 4a). At the genus level, we observed
S24_7, Odoribacter, and Oribacterium being associated
with severe RSV and Clostridiales and Coriobacteriaceae
being associated with moderate disease (Fig. 4b). The
specific microbes associated with genus and OTUs
are also shown in Fig. 4c. Furthermore, we used dis-
criminant analysis of principal components at the
OTU level in conjunction with one-way ANOVA with
Benjamini-Hochberg correction and Tukey’s range test
to further elucidate the microbial differences between
disease severity groups. We showed that specific
OTUs belonging to the Enterococcus, Lactobacillus,
Fig. 4 Linear discriminant analysis effect size (LEfSe) analysis of severe, moderate, and control shows six specific bacterial clades that distinguish severe
RSV from control or moderate RSV. The LEfSe analysis shows the linear effect size between the samples and calculates the linear discriminant analysis
(LDA) score for each of the Operation Taxonomic Units (OTUs) showing their respective ability to characterize the severity of disease. Taxonomic rank
is denoted by the first small letter in the naming. a LEfSe at the family level, (b) LEfSe at the genus level, and (c) LEfSe at the OTU level. All the
phylogenetic clades shown are p < 0.05 following non-parametric factorial Kruskal-Wallis (KW) sum-rank test and Wilcoxon rank-sum test
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Oscillospira, Odoribacter, Tissierella Soehngenia, and
S24_7 families were among the top bacterial taxa to
separate the specific microbiome characteristics between
the groups in a discriminant analysis of principal compo-
nents (DAPC) cluster graph (Fig. 5a). DAPC analysis uti-
lizes sequential K-means and model selection to infer
genetic clusters by focusing on between-group variability
and identifying the variables that best separate these
groups. This is further demonstrated by looking at the dis-
ease severity groups at the Family level. By inspecting the
percent abundance of the families demonstrated to separ-
ate the disease severity groups, S24_7 is increased in
severe patients compared to control patients while Morax-
ellaceae is decreased (Fig. 5b). At the genus level, S24_7 is
again increased in severe patients compared to control pa-
tients while Tissierella Soehngenia is decreased (Fig. 5c).
At the OTU level, we observed an increase in relative per-
cent abundance of S24_7 and Odoribacter with a decrease
in Tissierella Soehngenia, between severe and control RSV
(Fig. 5d). However, the most significant of these was
Fig. 5 Discriminant analysis of principal components (DAPC) plot (a) at OTU level revealed distinct clustering of severe patients (red), moderate
patients (yellow), and control patients (blue). Canonical loading plot stresses the specific OTUs most influential in the separation of clusters. b
Percent abundance with cumulative-sum scaling (CSS) + log transformation at the family level. c Percent abundance with CSS + log
transformation at the genus level. d Percent abundance with CSS + log transformation at the OTU level. Significance (p < 0.05) with BH correction
between control vs. moderate, control vs. severe, and moderate vs. severe is denoted by a, b, and c, respectively
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significant increases in S24_7 in severe patients compared
to moderate patients. This coincides with the LEfSe ana-
lysis, giving additional data showing that there is an asso-
ciation with S24_7 and severity of RSV disease.
Discussion
The lung and gut microbiome axis has increasingly been
studied over the last decade to elucidate the relationship
between microbiome dysbiosis and immunity in the lung
[16–22]. The gut-lung microbiome axis has been proposed
and studied for its ability to help regulate the immune
system [13, 22, 23]. Because there are a vast number of
microbes residing in the gut, there is no shortage of
microorganism-associated molecular patterns (MAMPs) as
well as pathogen-associated molecular patterns (PAMPs)
that can initiate in the gut and alter immune functions in
the lung [24]. MAMPs and PAMPS are able to activate
Toll Like Receptors (TLR) on dendritic cells, T cells, epi-
thelial cells, macrophages, and B cells. This activation of
TLRs can change cytokine, chemokine, and antibody pro-
duction in the lung, all of which have been shown to be
important in viral clearance for RSV [25, 26]. Studies have
shown associations between bronchiolitis and the gut
microbiome in infants, along with associations between
RSV and the gut microbiome of mice. In infants, these
studies demonstrated that there was a Bacteroides-
dominant profile that was associated with a higher likeli-
hood of bronchiolitis [27]. In mice, there was a significant
increase in Bacteroidetes and a decrease in Firmicutes
phyla abundance [13]. However, to our knowledge, our
study is the first to directly investigate the role of gut
microbiota in RSV disease severity in infants. Our findings
indicate that between RSV infected patients and control
patients there are no significant changes in the abundance
of microbes in the gut (Fig. 2a, b), but there is a significant
change in gut microbial composition between RSV infected
patients and control patients (Fig. 3a).
We observed significant enrichments in the families
S24_7, Clostridiales, Odoribacteraceae, Lactobacillaceae,
Actinomyces using LEfSe and ANOVA with BH correction
between these RSV and control patients. Likewise, our data
indicates that when looking at severity (PICU vs. Non-
PICU vs. Control), there is only a slight decrease in com-
mensal microbial abundance across the patient groups
(Fig. 2c, d). We do, however, see separate phylogenetic
clustering between the severe and moderate patients and
separation from the control patients (Fig. 3b). This cluster-
ing was shown to be dependent upon Enterococcus, Lacto-
bacillus, Oscillospira, Odoribacter, Tissierella Soehngenia,
and S24_7 (Fig. 4). The LEfSe analysis showed us 6 bacter-
ial OTUs that were enriched in the severe group when
compared to the moderate and control groups. Specifically,
a significant increase in S24_7 OTU 191 coincided with
severe versus moderate RSV (Fig. 5d). This data suggests
that the bacteria that are driving these differences are
encompassed within the Firmicutes and Bacteroidetes
phylum but are varied at the family and OTU levels illus-
trating unknown factors contributing to this dysbiosis of
the gut microbiome. Our study demonstrates that the gut
microbiome diversification is associated with RSV disease
severity and suggests that altering the gut microbiome may
have clinical relevance.
Despite the fact that S24_7 (aka Muribaculaceae or
Candidatus Homeothermaceae) has been shown to make
up a significant portion of the mouse and human intes-
tinal microbiome, there have been very few studies
investigating its role in immunity [13, 28, 29]. One study
characterizing 30 population genomes of S24_7 found
that 20 of the 30 populations’ genomes contain a metal-
loprotease belonging to M6 peptidase family. Peptidases
within this family exhibit antimicrobial capabilities as
well as degradation abilities for extracellular matrices
(ECM). In addition to M6 peptidase in their genomes,
11 of the 30 populations of S24_7 contained IgA degrad-
ing peptidase sequences in their genomes (peptidase
family M64). This could be crucial to the microbiome’s
interaction with RSV severity as it has been shown that
IgA is vital for mucosal defense in RSV infection and
aids in protection to upper respiratory tract infections
[30–34]. These mucosal antibodies have, similarly, been
shown to protect human adults from experimental RSV
infection [30, 35]. Therefore, IgA is important for pro-
tection and disruption of memory IgA can contribute to
severity and reoccurrence of RSV.
However, S24_7 is not the only potential mechanism
for IgA disruption originating in the gut microbiome.
The gut microbiome consists of thousands of com-
mensal bacteria, all of which, play an essential role in
immune response and development at an early age. The
gut microbiome produces several metabolites that enter
the intestinal lymphatic system allowing commensal
bacteria in the gut to modulate activation of B cells, den-
dritic cells [36], inflammatory cytokines, and production
of antibodies. Work in adult germ-free mice have dem-
onstrated that a lack of commensal bacteria inhabiting
the gut leads to fewer intraepithelial lymphocytes,
smaller peyer’s patches [37], fewer Th17 T cells [38],
and defective regulatory T cells [39]. In addition, human
gut bacteria such as Bacteroides fragilis have been shown
to regulate the balance between Th1 and Th2 cells in
the lung by producing polysaccharide A and inducing
INF-ɣ (Th1 T cells) [40]. While Clostridium and Clostri-
diales have been shown to induce regulatory T cell
(Treg) production [41]. In RSV infected patients, we
observed increases in the Clostridiales family suggesting
an induction of Tregs which are essential in the manage-
ment of RSV severity. As RSV evades the adaptive
immune response by skewing the Th1/Th2 balances
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toward a Th2 specific immune response, the balance
between Th1, Th2, and Treg cells are crucial to the patho-
genesis of RSV by reducing Th2 immune responses and
pulmonary eosinophilia [42]. Therefore, the microbiome
dysbiosis that we observe could be a source for T cell im-
balance and severe RSV disease. While it is enticing to
speculate that elevations in M6 peptidases due to enrich-
ment of S24_7 family members leads to degradation of
RSV specific IgA and disease severity, it is yet to be deter-
mined whether a gut microbial profile low in diversity and
enriched in S24_7 is the cause, or result, of severe RSV
disease. Mechanistic studies need to be done in order to
address this important question. It is possible that by elu-
cidating the mechanism of S24_7 in RSV disease severity
therapeutic targets could be identified.
Our findings highlight that there is a correlation between
RSV infection and dysbiosis of the gut microbiome. We
identified disruptions in the abundance of microbes in pa-
tients with severe RSV disease as well as characteristic
microbiome shifts in all RSV patients. We identified that
there were 6 specific, enriched microbes associated with
RSV severity. Together, our findings identified changes in
phylogenetic diversity in RSV patients and identified spe-
cific microbes associated with severity of disease. However,
there were limitations to this study. One of the limitations
of this study is the small sample size, particularly for severe
RSV patients. It is also noteworthy that this study was con-
ducted in Memphis, Tennessee where there is a socioeco-
nomic and racial skew in patient demographics that can be
a limitation to the extrapolation of these studies across
sites. It is unclear if the changes in gut microbiota are
causal or correlated with RSV (or hospitalization). Further
studies need to be done to characterize the change in gut
microbiota of RSV patients fully. Future work will include
additional patient recruitment to more precisely define a
gut microbial profile associated with severe RSV disease.
These studies could lead to the development of logistic re-
gression models to predict infants at high risk for severe
RSV disease based on gut microbiome.
Conclusions
Respiratory syncytial virus (RSV) is a ubiquitous respiratory
virus infecting the majority of the human population by 1
year of age. It is the number one cause of lower respiratory
tract infections in infants, yet there are still no vaccines or
specific antiviral therapies against RSV. Most patients in-
fected with RSV develop mild upper respiratory tract infec-
tions, but a percentage of patients develop severe lower
respiratory tract infections eliciting the need for intensive
care and sometimes resulting in death. While there have
been papers that show the interrelationships between gut
and nasal microbiome changes in RSV patients there has
been no data that observes the relationship between gut
microbiota and severity of RSV disease. This manuscript
makes the case that gut microbiome changes are associated
with severity of RSV disease and these changes could be
used to identify therapeutic targets or as biomarkers of
severe clinical RSV. The specific interaction of the gut
microbiome and respiratory immunity against RSV infec-
tions should be investigated in further studies.
Methods
Ethics statement
These studies were approved by the Institutional Review
Board at the University of Tennessee Health Science
Center and Louisiana State University.
Patient enrollment and sample collection
Patients were enrolled at Le Bonheur Children’s Hospital
in Memphis, Tennessee, during the RSV season in the
years 2014–2016. A total of 58 infants hospitalized with
RSV were enrolled in the study (Table 1). This work in-
cludes samples from 23 patients that were used in a study
recently submitted for publication and 33 patients used in
another study recently accepted for publication [43]. In-
clusion criteria were patients less than 12months old (1
control patient was 368 days old), informed consent from
parent or guardian, patients could not have a positive
blood culture within 72 h prior to collection of stool, pa-
tients could not be diagnosed with any immunodeficiency,
patients could not be on any antibiotics within 4 weeks
prior to enrollment, patients could not have been placed
on oxygen for more than 7 days within 3months prior to
the study, patients could not be receiving other investiga-
tional immunomodulatory or investigational antiviral
agents, patients could not have a hemodynamically signifi-
cant congenital heart disease, and patients must have
tested positive for RSV and negative for influenza, by RT-
PCR or be positive for RSV antigens tested by the hospi-
tal’s diagnostic lab. Among RSV positive patients, 5 infants
were admitted to the PICU and thus considered severe; 53
were admitted to the pediatric ward and considered mod-
erate. Healthy controls patients were enrolled from Le
Bonheur Outpatient Clinic during well-baby checkups.
Within 72 h of admission to the hospital, stool samples
from these infants were collected, and 100mg aliquots of
stool were stored at − 80 °C until DNA extraction.
16S sequencing
Fecal DNA was isolated from the 100 mg aliquots of
stool using QIAamp PowerFecal DNA Kit (Qiagen) ac-
cording to the manufacturer’s instructions. Fecal DNA
was sent to the University of Alabama at Birmingham
Center for Clinical and Translational Science for 16S se-
quencing. Unique barcoded primers were used to amp-
lify the hypervariable V4 regions of the bacterial 16S
rRNA gene from each sample. The resulting amplicon
libraries were then gel purified using QIAquick Gel
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Extraction Kit (Qiagen). Finally, the purified libraries
were sequenced using Next-generation sequencing per-
formed on the Illumina MiSeq system using 250 bp
paired-end reads (Fig. 1a). All generation of amplicon
libraries and sample preparation for loadings onto the
Illumina MiSeq system protocols were previously pub-
lished by Kumar et al. [44]
Bioinformatics
Sequence data with a minimum length of 250 base pairs
were processed and analyzed using QIIME 2 version
2018.4.0 (RRID: SCR_008249). Sequences were demulti-
plexed using Qiime 2 demux, passed through quality con-
trol using the deblur quality control method, and created
the phylogenetic tree using mafft program to perform a
multiple sequence alignment of the sequences and FastTree
to create an unrooted tree. The operational taxonomic
units (OTUs) were generated using a 99% identity and then
classified by phylogeny using the classifier from Green-
Genes database 13_8 [45, 46]. Subsequently, alpha diversity
measured using Shannon Index and Chao1 Index in
Qiime2, beta diversity, the community similarity, measured
via unweighted and weighted unifrac distance matrix and
PERMANOVA with 999 permutations was used to identify
significant features between groups. Linear discriminant
analysis effect size (LEfSe: RRID: SCR_014609) in Galaxy
(Fig. 1b) was used to discover biomarkers specific to
each of the patient groups. In Calypso, the data was
normalized using cumulative sum scaling (CSS)
normalization for multivariate tests. In order to ad-
dress false discovery rate two-way repeated-measures
analysis of variance (ANOVA) in conjunction with
Benjamini–Hochberg multiple-inference correction
with Dunnett’s correction was used to test for signifi-
cant differences in alpha diversity and differential taxa
abundance between groups. Significance was defined
as p < 0.05 after FDR adjustment (Prism v8.0, Graph-
Pad Software, La Jolla, CA) (Calypso). Quality control of
sample data can be found in (Supplemental Figure 1).
Data are presented as means ± SEM. The datasets gener-
ated for this study can be found in the SRA accession
database: PRJNA579491.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12866-020-01816-5.
Additional file 1: Figure S1. Quality control plots (A) rarefaction
analysis showing adequate reads for OTUs. (B) reads per sample showing
high read counts for all samples used.
Additional file 2: Figure S2. Bar chart illustrating the microbial
abundance differences between the control, moderate, and severe
patients at the (A) family level, (B) genus level, and (C) OTU level.
Additional file 3: Figure S3. Odds ratio showing the top 100
biomarkers associated with all RSV patients compared to control patients.
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